美国联合医疗 UTHR 深 沪
已收盘 12-19 16:00:00 美东时间
517.12
+10.120
+2.00%
华盛通- 最 高518.61
- 今 开505.45
- 成交量 49.82万股
- 最 低 470.13
- 昨 收 507.00
- 总市值 234.25亿
- 52周最高 518.61
- 市盈率 静 51.41
- 换手率 1.10%
- 52周最低 266.98
- 委 比 -86.78%
- 总股本 4529.95万
- 历史最高 518.61
- 量 比 1.11
- 振 幅 9.56%
- 历史最低 1.10
- 每 手 1
- 风险率 65.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多长风药业：国产替代叠加需求爆发，有望在吸入式制剂领域复刻英伟达与比亚迪的投资逻辑与叙事模型
（来源：蚌埠新闻网） 转自：蚌埠新闻网 2025年9月26日，长风药业股份有限公司正式启动全球公开发售，计划发行约4119.8万股H股，发售价定为每股14.7...
10-09 11:21
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
Liquidia's YUTREPIA, a treprostinil inhalation powder for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), is now available via specialty pharmacies following FDA approval on May 23, 2025. The commercial launch was achieved in just five business days and court denied a preliminary injunction against it. YUTREPIA aims to provide a new treatment option for patients with these conditions.
06-02 10:30
Key Takeaways From United Therapeutics Analyst Ratings
Analysts' ratings for United Therapeutics (NASDAQ:UTHR) over the last quarter v...
2024-09-24 01:00
Court Finds United Therapeutics' Interference With Launch of Generic Treprostinil Injection Caused Losses Of More Than $137M
Liquidia Corporation (NASDAQ:LQDA) (Liquidia), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today that the United States District Court for the
2024-09-16 21:43
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.
2024-09-06 23:52
Liquidia Seeks Stay on FDA Exclusivity Approval of Rival Version of Hypertension Drug
05:42 PM EDT, 08/28/2024 (MT Newswires) -- Liquidia (LQDA) is seeking a preliminary injunction on an Aug. 16 decision by the US Food and Drug Administration to keep its Yutrepia drug off the market until the exclusivity period for a rival medication expires May next year, according to court document...
2024-08-29 05:42
Ambarella To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Oppenheimer raised the price target for United Therapeutics Corporation (NASDAQ:UTHR) from $400 to $575. Oppen...
2024-08-28 21:16
Oppenheimer Raises United Therapeutics Price Target to $575 From $400, Maintains Outperform Rating
08:18 AM EDT, 08/28/2024 (MT Newswires) -- United Therapeutics (UTHR) has an average rating of outperform and price targets ranging from $221 to $575, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North...
2024-08-28 20:18
Liquidia Files Legal Challenge Against FDA Decision to Grant 3-Year New Clinical Investigation Exclusivity to Tyvaso DPI
07:09 AM EDT, 08/22/2024 (MT Newswires) -- Liquidia (LQDA) said Thursday it has filed a legal challenge to the US Food and Drug Administration's recent decision to grant a three-year new clinical investigation exclusivity to United Therapeutics' (UTHR) Tyvaso DPI. The complaint was filed with the US...
2024-08-22 19:09
The Analyst Verdict: United Therapeutics In The Eyes Of 8 Experts
In the last three months, 8 analysts have published ratings on United Therapeutics (NASDAQ:UTHR), offering a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing ...
2024-08-21 01:00
